Close Icon We use cookies to improve your website experience. To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy. By continuing to use the website, you consent to our use of cookies.

Pharma Intelligence is part of the Informa Intelligence Division of Informa PLC

This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Products:

Pharma Consulting

Conferences 2020

Awards

Upcoming Webinars

Webinar recordings

Close Icon

Global Search Configuration

Search Site Products & Services
Close Icon

Search by Keyword

Focus
Needs

Get ahead with in-depth pharmaceutical competitive intelligence

Stay on top of the rapidly changing competitive landscape with detailed insight and intelligence on key industry, commercial, clinical, regulatory, and R&D events.

Master the marketplace

To succeed in the pharmaceutical marketplace, it’s vital to stay up to date with developments that can affect your business. Our competitive and market intelligence can give you all the credible, detailed information you need in one place.

What we offer

You can quickly access referenced information across global key industry developments in the pharmaceutical and medical technology markets with our easy-to-use solutions and expert analysts.

Build detailed competitive and market landscape analyses quickly, with access to global information on:

Drug and device development
Patient populations
Clinical trials
Drug and device patents
Market moving events
Patient-based sales forecasts

How it helps

We help you more accurately:

Prioritize pharmaceutical R&D spend by finding gaps and unmet needs through the analysis of competitors’ targets and R&D priorities
Understand disease epidemiology and disease sub-populations targeted in clinical development
Anticipate market changes through patent expiration tracking
Earmark who is entering or exiting your market via licensing or acquisition, as well as who is securing or providing funding
Project revenue for your pipeline and marketed drugs

Relevant products

Datamonitor Healthcare: data analysis and insight

Datamonitor Healthcare's expert coverage of key diseases, companies, drugs and market trends makes it the go-to product for pharmaceutical and biotechnology companies to support the development and validation of their strategic plans and commercial decisions.

Key benefits:

Prioritize market opportunities
Identify unmet needs
Make informed decisions

Biomedtracker: see the drug development process through analysts’ eyes

Real-time tracking and analysis of the drug development pipeline

Key benefits:

Market Events & Catalysts
Likelihood of Approval
Deals Coverage

Scrip: industry news and insights

Key benefits:

Follow market developments
Go beyond the news
Hear from news makers

View all content

Datamonitor Healthcare

Priority Populations For COVID-19 Vaccination: Global Timelines For Deployment

As the COVID-19 pandemic continues, governments worldwide have pinned their hopes on returning to normality on the development of a vaccine. With multiple vaccines currently in late-stage trials, there is promise that a successful vaccine will soon be ready.

Topic Coronavirus Vaccines

View white paper
Biomedtracker, Meddevicetracker

Q4 Outlook Report 2020

The world-class data contained in this report extract will keep you up to speed on the drug development landscape for better decision-making

View article
Scrip

Quick Listen: Scrip's Five Must-Know Things

Take a brief audio tour around the main biopharma industry events of the past week, as brought to you by Scrip's global team, in this podcast version of Five Must-Know Things.

Topic Coronavirus M A

Full podcast
Scrip

Novartis's Canakinumab Fails In COVID-19 Pneumonia Patients

Drug fails to save lives in study and follows disappointments from Roche and Regeneron/Sanofi's IL-6 inhibitors.

Topic Coronavirus Clinical Trials

View article
Scrip

Pfizer And BioNTech Claim COVID19 Vaccine Success

The companies look to have secured a better than expected 90% efficacy level, but will await safety data before filing later this month.

Topic Coronavirus BioPharmaceutical

View article
Scrip

Quick Listen: Scrip's Five Must-Know Things

Join us for a quick audio roundup of major developments in the international biopharma industry over the past week, as covered by Scrip's global team.

Topic Sales Earnings

Full podcast
Scrip

Slow And Steady: Merck Advances COVID-19 Antiviral, Vaccine Programs

Merck’s third quarter beat analyst consensus and the company raised its guidance. The COVID-19-battered vaccines business began to improve but Gardasil’s recovery was slower than expected.

Topic Coronavirus Sales Earnings Business Strategies

View article
Scrip

Pfizer's Bourla Urges Patience As COVID-19 Vaccine Data Timeline Lags

Highly anticipated data from Pfizer's Phase III COVID-19 vaccine trial does not appear on track to be made publicly available in October as previously expected.

Topic Coronavirus Vaccines Sales Earnings

View article
Scrip

Scrip Asia 100 Report Extract

In a year epitomized by a global pandemic, the depth and implications of pharma activity across Asia has been staggering. Gain unique insight into the companies, products and themes leading the industry when you download the Scrip Asia 100 Report, written by our experienced on-the-ground journalists throughout this vast region.

Topic Business Strategies

Single report
Scrip

Quick Listen: Scrip's Five Must-Know Things

Join us for a brief audio roundup of the major developments in the international biopharma industry over the past week, as covered by Scrip's global team

Topic Coronavirus Research & Development

Full podcast
Scrip

Stockwatch: Pandemic And Biosimilar Effects Subordinate Early Third-Quarter Earnings Results

Early in 2020, company guidance was that pandemic-related effects would have dissipated in the third quarter. Issues specific to J&J and Roche leave this broad conclusion still up in the air

Topic Sales Earnings Coronavirus

View article
Scrip

Merck KGaA Exec On Innovating Vaccine Manufacturing To Tackle Outbreaks

The head of global vaccine and plasma segments, bioprocessing, at German multinational Merck discusses key aspects around evolving vaccine manufacturing to improve the efficiency and speed of response during a pandemic. Pre-existing manufacturing platforms, the executive says, could compress process development work and fast-track scale-up

Topic Vaccines Coronavirus

View article
Scrip, Datamonitor Healthcare

Top 10 Best-Selling Drugs of 2019

In 2019, the 10 most lucrative medicines generated combined global sales of $92.5B. Scrip provides insight into these top sellers and the companies behind them, as well US dynamics, global sales forecasts and lifecycle data, with complementary market analysis from Datamonitor Healthcare on diseases targeted, indications, and more.

Topic Drug Review Diseases

Single report
Scrip

2020’s Most Significant Cancer Deals

Gain insights into the oncology deals making headlines with exclusive reporting and analysis from Scrip. Explore a snapshot view of the year’s biggest oncology deals so far, in a convenient infographic and go deeper into two major cancer deals that occurred in September with your free article pack.

Topic Cancer Deals

Single report
Scrip

Quick Listen Scrips Five Must Know Things

Join us for an audio roundup of major events in the international biopharma industry over the past week, as covered by Scrip's global team

Topic Coronavirus Research & Development Clinical Trials

Full podcast